Sulbactam sodium/ampicillin sodium (SBT/ABPC) 3g, QID for the treatment of moderate to severe community-acquired pneumonia (CAP): the first evidence from Japan

摘要

Background: SBT/ABPC 3?g, QID is approved by regulatory authorities and widely used for moderate to severe community-acquired pneumonia (CAP) in the EU, USA, China, and South Korea but not in Japan. However, there had been no evidence for efficacy and safety of SBT/ABPC 3?g, QID from clinical trials for moderate to severe CAP worldwide. We conducted the first phase 3 trial of SBT/ABPC 3?g, QID in Japanese adults to evaluate efficacy and safety in moderate to severe CAP.